Utah Medical Products Inc. Announces Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017
January 30, 2018 at 09:00 am
Share
Utah Medical Products Inc. announced audited consolidated earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported net sales of $10,201,000 compared to $8,852,000 a year ago. Operating income of $4,573,000 compared to $3,621,000 a year ago. Net loss was $2,522,000 or $0.674 per share compared to profit of $2,717,000 or $0.725 per share a year ago. Income before income tax was $4,578,000 against $2,717 for the last year.
For the year, the company reported net sales of $41,414,000 compared to $39,298,000 a year ago. Operating income of $19,011,000 compared to $16,187,000 a year ago. Net income was $8,505,000 or $2.276 per share compared to $12,128,000 or $3.220 per share a year ago. Income before income tax was $14,562,000 against $12,128 for the last year.
Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety.